Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:04 AM
Ignite Modification Date:
2025-12-25 @ 1:04 AM
NCT ID:
NCT00031993
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed squamous cell carcinoma (SCC) of the cervix
* Persistent or recurrent progressive disease
* At least 1 prior systemic chemotherapy regimen for management of advanced, metastatic, or recurrent SCC of the cervix is required
* Chemotherapy administered as a radiosensitizer in conjunction with radiotherapy does not count as a systemic chemotherapy regimen
* At least 1 unidimensionally measurable target lesion
* At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
* Lesions within a previously irradiated field are considered nontarget lesions unless disease progression or persistence is confirmed ≥ 90 days after completion of radiotherapy
* Tumor accessible for repeat needle biopsy
* Ineligible for a higher priority Gynecologic Oncology Group (GOG) protocol (any active GOG phase III protocol for the same patient population)
* Performance status - GOG 0-2 (for patients who have received only 1 prior regimen)
* Performance status - GOG 0-1 (for patients who have received 2 prior regimens)
* Platelet count at least 100,000/mm\^3
* Absolute neutrophil count at least 1,500/mm\^3
* Bilirubin no greater than upper limit of normal (ULN)
* SGOT no greater than 2.5 times ULN
* Alkaline phosphatase no greater than 2.5 times ULN
* Creatinine no greater than 1.5 times ULN
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
* No abnormalities of the cornea (e.g., dry eye syndrome or Sjogren's syndrome)
* No congenital abnormalities (e.g., Fuch's dystrophy)
* No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
* No abnormal corneal sensitivity test (Schirmer test or similar tear production test)
* No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
* No uncontrolled concurrent illness
* No ongoing or active infection requiring IV antibiotics
* No psychiatric illness or social situation that would preclude study compliance
* No grade 2 or greater sensory or motor neuropathy
* No prior allergic reactions attributed to compounds of similar chemical or biological composition to erlotinib
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* At least 3 weeks since prior immunologic therapy for SCC of the cervix
* One additional prior cytotoxic chemotherapy regimen for recurrent or persistent disease allowed
* At least 3 weeks since prior chemotherapy for SCC of the cervix and recovered
* No prior non-cytotoxic chemotherapy for recurrent or persistent disease
* At least 3 weeks since prior hormonal therapy for SCC of the cervix
* At least 3 weeks since prior radiotherapy for SCC of the cervix and recovered
* Recovered from recent prior surgery
* At least 3 weeks since other prior therapy for SCC of the cervix
* No prior epidermal growth factor receptor-targeting therapies
* No prior anticancer treatment that would preclude study participation
* No other concurrent investigational or commercial agents or therapies for SCC of the cervix
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT00031993
Study Brief:
Protocol Section:
NCT00031993